SCHEMBL412803

SCHEMBL412803

NC(C(=O)O)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531463 1.00
SCHEMBL412802 1.00
Hydrochloric Acid SCHEMBL17423095 0.97
Hydrochloric Acid SCHEMBL17423093 0.97
SCHEMBL1764006 0.90 DPP4 (0.47)
SCHEMBL342059 0.90 DPP4 (0.46)
SCHEMBL650638 0.90 DPP4 (0.46)
SCHEMBL17729296 0.90 DPP4 (0.47)
SCHEMBL7077492 0.90 DPP4 (0.46)
SCHEMBL12003240 0.90 DPP4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025079064-A1 INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS PEPTICOM LTD. (IL) 2025-04-17 WO claimed
CN-115957294-A Beneficial effects of supplementation with N-acetylcysteine and glycine to improve glutathione levels 贝勒医学院 2023-04-14 CN claimed
US-20210115087-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS UNIV ROCHESTER (US) 2021-04-22 US claimed
US-20190241615-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS UNIVERSITY OF ROCHESTER 2019-08-08 US claimed
EP-3475294-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS The University of Rochester (US) 2019-05-01 EP claimed
WO-2017223207-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS UNIVERSITY OF ROCHESTER (US) 2017-12-28 WO claimed
CN-106479278-A Self-cleaning type air cleaning powdery paints and preparation method thereof 金福兴 2017-03-08 CN claimed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 EP disclosed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 WO disclosed
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 US disclosed
US-20250276995-A1 PRODUCTION METHOD FOR PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-04 US disclosed
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 EP disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 EP disclosed
US-6288037-B1 C-TERMINALLY MODIFIED PENTAPEPTIDES CONTAINING VALINE AND ASPARTIC ACID BASF AKTIENGESELLSCHAFT (DE) 2001-09-11 US disclosed
WO-2001064678-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-07 WO disclosed
WO-2001040262-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-07 WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed
EP-0880542-A2 SUBSTRATES AND INHIBITORS FOR CYSTEINE PROTEASE ICH-1 BASF AG (US) 1998-12-02 EP disclosed
WO-1997027220-A2 SUBSTRATES AND INHIBITORS FOR CYSTEINE PROTEASE ICH-1 BASF AG (US) 1997-07-31 WO disclosed